In the B16.F10 melanoma model, endothelial expression of ICAM-1 and VCAM-1 was not changed after treatment with agonistic CD40-antibody or sunitinib alone, but combining these treatments led to a synergistic increase in ICAM-1 (p=0.043, Figure 4A) and VCAM-1 (p=0.017, Figure 4B) surface expression. The gene discussed is VCAM1; the disease is melanoma.